Drugs / SAR402663
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06660667 | Nov 2024 → May 2027 expected | wet macular degeneration | Sanofi | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-11 | Sanofi | Regulatory Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration sanofi.com ↗
The US Food and Drug Administration (FDA) has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-11 | Sanofi | Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration sanofi.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR402663 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06660667 ↗ |
| Route | Intravitreal | “Route of administration:Intravitreal injection” NCT06660667 ↗ |